Ryvu Therapeutics Announces Poster Presentations at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium

We are excited to present updated clinical and preclinical data on RVU120 and our novel MTA-cooperative PRMT5 inhibitors at this years AACR-NCI-EORTC symposium," said Hendrik Nogai, M.D., Chief Medical Officer of Ryvu Therapeutics.